DAVITA INC.

ISIN: US23918K1088 WKN: 23918K108 Asset Class: Stock



Company Profile

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Financial figures, Fiscal year: from 01.01. to 31.12.

	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity
Current assets	3,137,906,000		3,155,292,000		3,167,723,000	
Common stock capital		89,000		90,000		97,000
Fixed assets	14,481,571,000		14,524,459,000		14,703,283,000	
Equity capital of a company		2,743,350,000		2,224,800,000		2,370,980,000
Cash and cash equivalents	464,634,000		338,989,000		554,960,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		2,642,214,000		2,619,747,000		2,398,533,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		12,233,913,000		12,835,204,000		13,101,493,000
Different income		-		-		-
Other liabilities		183,074,000		105,233,000		119,158,000
Total assets	17,619,477,000	17,619,477,000	17,679,751,000	17,679,751,000	17,871,006,000	17,871,006,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	70,000	70,000	69,000
Equity ratio	25.15%	21.14%	22.31%
Debt-equity ratio	297.68%	373.07%	348.29%

Others

	2023	2022	2021
Tax Expense Rate	18.70%	20.50%	20.20%

DAVITA INC.

ISIN: US23918K1088 WKN: 23918K108 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	12,140,147,000	11,609,894,000	11,618,797,000
Net income	691,535,000	546,948,000	978,450,000
EBIT	1,378,160,582	1,232,074,757	1,687,293,426
Operating income before taxes	1,177,094,000	966,278,000	1,518,494,000
Cash Flow	2,063,944,000	1,568,532,000	1,933,820,000
Net interest income	-304,162,000	-357,964,000	-295,020,000
Research and development expenses	-	-	-
Income taxes	220,116,000	198,087,000	306,732,000
Result from investments in subsidaries, associates and other	-	-	-
Revenues per employee	161,360	154,312	156,669

Board of Directors

Members of Management Board		
Pamela Arway	Chairman of Board of Directors	
Gregory Moore	Member of Board of Directors	
Adam Schechter	Member of Board of Directors	
Barbara Desoer	Member of Board of Directors	
Charles Berg	Member of Board of Directors	
Dennis Pullin	Member of Board of Directors	
Jason Hollar	Member of Board of Directors	
Phyllis Yale	Member of Board of Directors	
Wendy Schoppert	Member of Board of Directors	
Javier J. Rodriguez	Chairman of Managing Board	
Christopher M. Berry	Member of Executive Committee	
James O. Hearty	Member of Executive Committee	
Jeffrey A. Giullian	Member of Executive Committee	
Joel Ackerman	Member of Executive Committee	
Kathleen A. Waters	Member of Executive Committee	
Kenny Gardner	Member of Executive Committee	
Michael D. Staffieri	Member of Executive Committee	
Robert Lang	Member of Executive Committee	